JS 015
Alternative Names: JS-015Latest Information Update: 28 Aug 2026
At a glance
- Originator Shanghai Junshi Biosciences
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; DKK1 protein inhibitors; Myeloid-derived suppressor cell inhibitors; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 28 Aug 2026 Shanghai Junshi Bioscience completes a Phase I/II trial in Solid tumours (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease) in China (IV) (NCT06139211)
- 28 Apr 2026 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (IV, Infusion)
- 17 Apr 2024 Fudan University plans a phase I/II FD-IMPACT trial for Pancreatic Cancer in China (IV) (NCT06370754)